

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

SYNTHESIS AND ANTIVIRAL ACTIVITY OF NOVEL EXOMETHYLENE CYCLOPROPYL NUCLEOSIDES

Bo Gil Choi^a; Eun Yee Kwak^a; Joon Hee Hong^b; Chong Kyo Lee^c

^a Department of Medicinal Chemistry, College of Pharmacy, Chonnam National University, Kwangju, Korea ^b Department of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul, Korea ^c Pharmaceutical Screening Center, Korea Research Institute of Chemical Technology, Taejeon, Korea

Online publication date: 31 March 2001

To cite this Article Choi, Bo Gil , Kwak, Eun Yee , Hong, Joon Hee and Lee, Chong Kyo(2001) 'SYNTHESIS AND ANTIVIRAL ACTIVITY OF NOVEL EXOMETHYLENE CYCLOPROPYL NUCLEOSIDES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1059 – 1062

To link to this Article: DOI: 10.1081/NCN-100002491

URL: <http://dx.doi.org/10.1081/NCN-100002491>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ANTIVIRAL ACTIVITY OF NOVEL EXOMETHYLENE CYCLOPROPYL NUCLEOSIDES

Bo Gil Choi,^{1,*} Eun Yee Kwak,¹ Joon Hee Hong,²
and Chong Kyo Lee³

¹Department of Medicinal Chemistry, College of Pharmacy, Chonnam
National University, Kwangju 500-757, Korea

²Department of Medicinal Chemistry, College of Pharmacy, Ewha
Womans University, Seoul 120-720, Korea


³Pharmaceutical Screening Center, Korea Research Institute of
Chemical Technology, Taejon 306-600, Korea

ABSTRACT

Novel cyclopropyl nucleosides were synthesized as potential antiviral agents. The key intermediate **5**, prepared from Feist's acid **1** was condensed with purine derivatives by the S_N2 type reaction. All the synthesized compounds were evaluated for antiviral activity.

The discovery of novel nucleosides as antiviral and anticancer agents has been the goal of research of nucleoside chemist for a few decades (1). Structures which include analogues having furanose carbohydrate or various modifications thereof (e.g., cyclopentane and dioxo- and oxathiacyclopentane) exhibit diverse biological effects. The relevant examples are anti-HIV agents including AZT, 3TC (lamivudine) and abacavir. However, the toxicities associated with these nucleosides and the emergency of resistant viral strains prompt medicinal chemists to search for additional novel and structurally diverse compounds. Removal of part or parts of nucleosides furanose moiety resulting in a substantial simplification of the structure led in many cases to new antiviral agents of significant therapeutic potency.

*Corresponding author.



Scheme. Reagents: a) cat.H₂SO₄, methanol, 25°C, 18 h; b) LAH, ether, 0°C to reflux; c) TBDPSCI, imidazole, CH₂Cl₂, 0°C, 1.5 h; d) *p*-TsCl, DMAP, CH₂Cl₂, 0°C i h; e) adenine, K₂CO₃, 18-crown-6, DMF, 60°C, 3 h; f) 6-chloropurine, K₂CO₃, 18-crown-6, DMF, 60°C, 3 h; g) 2-amino-6-chloropurine, K₂CO₃, 18-crown-6, DMF, 60°C, 2 h; h) *n*-Bu₄NF, THF, rt, 2 h; i) NaOCH₃, 2-mercaptoethanol, methanol, reflux, 20 h; j) NH₃/methanol, 90°C, 24 h.

Acyclonucleosides can be considered as derivative of classical nucleosides or carbo-nucleosides by “removing” one or more bonds from the cyclic moiety (2). Because of their structural flexibility, many of them possess biological properties despite their lack of chirality such as acyclovir (3) and ganciclovir (4) as antiherpetic drugs. Recently, Zemlicka *et al.* described a new class of nucleoside analogues in which the ribofuranoside moiety is replaced with a methylene-cyclopropane structure (5). Among them, purine derivatives such as synadenol (6) and synguanol (5) exhibit potent antiviral activity, particularly against human cytomegalovirus (HCMV). Also, trisubstituted cyclopropane nucleosides with an additional hydroxy-methyl group at 1'-position were prepared by Sekiyama *et al.* (7). Among them, the guanine derivative (A-5021) showed more potent antiviral activity against HSV-1 than acyclovir and penciclovir and comparable for varicella zoaster virus (VZV) but ineffective

against HIV. Encouraged by these interesting structure and antiviral activity, we have determined to synthesize a novel class of nucleosides comprising a rigid exomethylene cyclopropyl backbone.

In order to synthesize the desired nucleosides, Feist's acid (**8**) **1** was selected as starting material (Scheme). Treatment of the Feist's acid with methanol and catalytic sulfuric acid gave diester **2**, which was reduced to diol **3** with lithium aluminum hydride in anhydrous ether solvent by refluxing. The diol **3** was carefully protected by sterically demanding *tert*-butyldiphenylsilyl group, and the mono-protected compound **4** was separated by silica gel column chromatography. In order to alkylate the sugar moiety by S_N2 type reaction, the compound **4** was activated to tosylate intermediate using *p*-toluene sulfonyl chloride in CH₂Cl₂ in the presence of DMAP at 0°C. The tosylate **5** was coupled with adenine, 6-chloropurine, and 2-amino-6-chloropurine in the presence of potassium carbonate and 18-crown-6 in DMF at 60°C to obtain the protected cyclopropyl nucleosides **6**, **7**, and **8**, respectively, and the 7-isomers were also synthesized in the case of **7** and **8**. Compounds **6**, **7**, and **8** were deprotected by *n*-Bu₄NF in THF to give the final nucleosides **9** (**9**), **10** (**10**), and **12** (**11**). Compounds **10** and **12** were hydrolyzed with mercaptoethanol and sodium methoxide under reflux in methanol to obtain hypoxanthine derivative **11** (**12**) and guanine derivative **13** (**13**), respectively. Treatment of compound **12** were with ammonia in methanol at 90°C gave 2,6-diaminopurine nucleoside **14** (**14**).

In summary, we have synthesized novel exomethylene cyclopropyl purine nucleosides. The key intermediate **5**, prepared from Feist's acid **1** was condensed by the S_N2 type reaction. From the synthesis, several purine nucleoside analogues have been obtained and their structures have been investigated by various spectroscopical studies. However, none of the evaluated compounds showed any significant antiviral activity against HSV-1, HSV-2, HCMV, HIV-1, HIV-2, and HBV up to 100 μM.

ACKNOWLEDGMENT

This article was supported in part by Research Fund for Sabbatical Year, Chonnam National University and it was greatly appreciated.

REFERENCES

1. Chu, C.K.; Baker, D.C., (Eds), *Nucleosides and Nucleotides as Antitumor and Antiviral Agents*; Plenum Press: New York, **1993**.
2. Agrofoglio, L.A.; Challand, S.R. *Acyclic, Carbocyclic and L-Nucleosides*; Kluwer Academic Publisher; Dordrecht, **1998**.
3. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P., Beauchamp, L.; Schaeffer, H.J. *Proc. Natl. Acad. Sci. USA*. **1977**, *74*, 5716.
4. Martin, J.C.; Dvorak, C.A.; Smee, D.F.; Matthews, T.R.; Julien, P.H.; Verheyden, J.P.H. *J. Med. Chem.* **1983**, *26*, 759.



5. Qiu, Y.-L.; Ksebati, M.B.; Ptak, R.G.; Fan, B.Y.; Breitenbach, J.M.; Lin, J.-S.; Cheng, Y.-C.; Kern, E.R.; Drach, J.C.; Zemlicka, J. *J. Med. Chem.* **1998**, *41*, 10.
6. Qiu, Y.-L.; Hempel, A.; Camerman, N.; Camerman, A.; Geiser, F.; Ptak, R.G.; Breitenbach, J.M.; Kira, T.; Li, L.; Gullen, E.; Cheng, Y.-C.; Drach, J.C.; Zemlicka, J. *J. Med. Chem.* **1998**, *41*, 5257.
7. Sekiyama, T.; Hatsuya, S.; Tanaka, Y.; Uchiyama, M.; Ono, N.; Iwayama, S.; Oikawa, M.; Suzuki, K.; Okunishi, M.; Tsuji, T. *J. Med. Chem.* **1998**, *41*, 1284.
8. Bromquist, A.T.; Longone, D.T. *J. Am. Chem. Soc.* **1959**, *81*, 2012.
9. Compound **9**: white solid; m. p. 198–199°C; IR (KBr) cm^{-1} : 3274–3162 (OH, NH_2); UV (MeOH) λ_{max} 262 (ϵ 8700); ^1H -NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.19, 8.14 (each 1H, s, $\text{C}^2\text{-H}$, $\text{C}^8\text{-H}$), 7.17 (2H, s, NH_2), 5.46 (1H, s, $\text{CH}_2=\text{C}$), 5.38 (1H, s, $\text{CH}_2=\text{C}$), 4.70 (1H, t, $J = 5.5$ Hz, OH), 4.24 (1H, dd, $J = 6, 14.0$ Hz, CH_2N), 4.03 (1H, dd, $J = 7.6, 14.0$ Hz, CH_2N), 3.44, 3.17 (each 1H, m, CH_2O), 1.80 (2H, m, $2 \times \text{cyPr CH}$).
10. Compound **10**: white solid ; m. p. 96–98°C; IR (KBr) cm^{-1} : 3312 (OH) : UV (MeOH) λ_{max} 264 (ϵ 7400); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.80, 8.87 (each 1H, s, $\text{C}^2\text{-H}$, $\text{C}^8\text{-H}$), 5.48, 5.41 (each 1H, s, $\text{CH}_2=\text{C}$), 4.68 (1H, t, $J = 5.55$ Hz, OH), 4.46 (1H, dd, $J = 5.8, 14.2$ Hz, CH_2N), 4.16 (1H, dd, $J = 8.2, 14.2$ Hz, CH_2N), 3.49, 3.11 (each 1H, m, CH_2O), 1.86 (2H, m, $2 \times \text{cyPr CH}$).
11. Compound **11**: white solid; m. p. 212–213°C; IR (KBr) cm^{-1} : 3371 (OH), 1677 (lactam $\text{C}=\text{O}$); UV (MeOH) λ_{max} 250 (ϵ 19200); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 12.26 (1H, bs, $\text{C}^6\text{-OH}$), 8.14, 8.03 (each 1H, s, $\text{C}^2\text{-H}$, $\text{C}^8\text{-H}$), 5.46, 5.38 (each 1H, s, $\text{CH}_2=\text{C}$), 4.70 (1H, t, $J = 5.4$ Hz, CH_2OH), 4.24 (1H, dd, $J = 5.6, 14.2$ Hz, CH_2N), 4.03 (1H, dd, $J = 7.8, 14.2$ Hz, CH_2N), 3.46 (1H, m, CH_2O), 3.16 (1H, m, CH_2O), 1.79 (2H, m, $2 \times \text{cyPr CH}$).
12. Compound **12**: white solid ; m. p. 183–185°C; IR (KBr) cm^{-1} : 3326–3221 (OH, NH_2); UV (MeOH) λ_{max} 310 (ϵ 11900); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 8.28 (1H, s, $\text{C}^8\text{-H}$), 6.89 (2H, bs, NH_2), 5.47, 5.40 (each 1H, s, $\text{CH}_2=\text{C}$), 4.69 (1H, t, $J = 5.4$ Hz, OH), 4.17 (1H, dd, $J = 5.8, 14.2$ Hz, CH_2N), 3.92 (1H, dd, $J = 7.9, 14.2$ Hz, CH_2N), 3.47, 3.14 (each 1H, m, CH_2O), 1.79 (2H, m, $2 \times \text{cyPr CH}$).
13. Compound **13**: white solid. m. p. 257°C; IR (KBr) cm^{-1} : 3150–174 (OH, lactam NH , NH_2), 1687 (lactam $\text{C}=\text{O}$) : UV (MeOH) λ_{max} 254 (ϵ 8500). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 10.56 (1H, bs, $\text{C}^6\text{-OH}$), 7.73 (1H, s, $\text{C}^8\text{-H}$), 6.43 (2H, bs, NH_2), 5.46, 5.39 (each 1H, s, $\text{CH}_2=\text{C}$), 4.7 (1H, t, $J = 5.5$, OH), 4.01 (1H, dd, $J = 5.7, 14.2$ Hz, CH_2N), 3.84 (1H, dd, $J = 7.6, 14.2$ Hz, CH_2N), 3.44, 3.18 (each 1H, m, CH_2O), 1.75, 1.73 (each 1H, m, cyPr CH).
14. Compound **14**: white solid; m. p. 209–210°C; IR (KBr) cm^{-1} : 3457–3170 (OH, NH_2); UV (MeOH) λ_{max} 256 (ϵ 7100), 282 (ϵ 8800); ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.75 (1H, s, $\text{C}^8\text{-H}$), 6.62, 5.75 (each 2H, bs, $2 \times \text{NH}_2$), 5.46, 5.39 (each 1H, s, $\text{CH}_2=\text{C}$), 4.7 (1H, t, $J = 5.5$, OH), 4.02 (1H, dd, $J = 6.0, 14.1$ Hz, CH_2N), 3.85 (1H, dd, $J = 7.5, 14.1$ Hz, CH_2N), 3.43, 3.19 (each 1H, m, CH_2O), 1.75 (2H, m, $2 \times \text{cyPr CH}$).



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002491>